clinical trial failure

Immutep shares plummet 82.6% after discontinuing Phase III trial for eftilagimod alfa due to futility, triggering class action investigation by Rosen Law Firm.

Compass Therapeutics faces securities investigation after lead drug tovecimig fails overall survival endpoint in COMPANION-002 trial, triggering significant stock losses.

Nektar Therapeutics faces securities fraud lawsuit over failed alopecia trial and alleged protocol disclosure violations. Stock fell 7.8% on December 16, 2025.

Rezolute's lead drug candidate failed Phase 3 trials, triggering massive stock collapse and securities fraud investigation by Portnoy Law Firm.

Pomerantz LLP filed class action against $NKTR over REZOLVE-AA trial failure. Stock dropped 7.77% after December disclosure of ineligible patient enrollment issues.

Merck shares dropped 4% after Phase 3 cancer trial failure, but FDA approval of HIV treatment Idvynso provided partial offset.

Immutep's $IMMP shares plummeted after discontinuing Phase III trial for cancer drug. Rosen Law Firm investigates potential securities fraud claims.

Portnoy Law Firm launches class action against $IMNB following failed Phase 2 glioblastoma trial, citing investor losses from steep stock decline.

Immutep's $IMMP stock crashed 82.6% after discontinuing Phase III trial for lead drug candidate. Rosen Law Firm investigating potential securities violations and class action claims.

Nektar Therapeutics ($NKTR) faces securities fraud lawsuit after Phase 2b alopecia trial failed due to enrollment violations, triggering 7.8% stock decline.

Pomerantz LLP sues Nektar Therapeutics for alleged securities fraud over failed clinical trial enrollment; stock falls 7.77%.

Robbins LLP sued Aldeyra Therapeutics over alleged investor misrepresentation regarding failed drug reproxalap. FDA rejected approval; stock fell 70.7%. Lead plaintiff deadline: May 29, 2026.

Mereo BioPharma faces class action lawsuit alleging false statements about failed Phase 3 clinical trials. Investors can join by April 6, 2026.

Pomerantz Law Firm files securities fraud lawsuit against $MREO after failed Phase 3 trials tank stock 87.7%. Lead Plaintiff deadline: April 6, 2026.

Robbins LLP files class action against Nektar Therapeutics for allegedly concealing REZOLVE-AA trial protocol violations, triggering 7.77% stock decline after trial failure announcement.

Immutep's $IMMP stock crashed after trial discontinuation announcement. Rosen Law Firm investigates securities claims for investor losses.

Three major companies face securities class action lawsuits over disclosure failures: $RARE for clinical trial misstatements, Driven Brands for financial controls, and $SMCI for undisclosed Chinese sales.

Mereo BioPharma faces class action lawsuit alleging false statements about failed Phase 3 trials ORBIT and COSMIC; investors in $MREO securities from June 2023-December 2025 urged to act by April 6, 2026 deadline.

Disc Medicine faces securities probe after FDA rejects bitopertin drug; stock slides 22% on February 13, 2026.

Ultragenyx stock crashes 42% after disclosing failed Phase 3 trial for setrusumab; investors with losses exceeding $100,000 have until April 6, 2026 to file lead plaintiff applications in class action lawsuit.